

# Summary and Work Group Considerations

Lisa Grohskopf, MD, MPH

Influenza Division, CDC

Advisory Committee on Immunization Practices

February 27, 2019

# Acknowledgments

## **Influenza Division**

Elif Alyanak

Noreen Alabi

Lenee Blanton

Lynnette Brammer

Joe Bresee

Alicia Budd

Jessie Chung

Josh Doyle

Jill Ferdinands

Brendan Flannery

Alicia Fry

Dan Jernigan

Jackie Katz

Krista Kniss

Sankan Nyanseor

Manish Patel

Mark Thompson

Jerry Tokars

Tim Uyeki

## **Immunization Safety Office**

Karen Broder

Frank Destefano

Penina Haber

Tom Shimabukuro

## **Immunization Services Division**

Sam Graitcer

Andrew Kroger

Amy Parker Fiebelkorn

Jeanne Santoli

# Influenza Vaccines for Young Children— *Recent Licensure Changes*

- ***Afluria (IIV3) and Afluria Quadrivalent (IIV4, Seqirus):***
  - Age indication expanded from  $\geq 5$  years to  $\geq 6$  months in October 2018
  - Children aged 6 through 35 months receive smaller dose volume
    - 0.25mL, vs. 0.5mL for those aged  $\geq 3$  years
  
- ***Fluzone Quadrivalent (IIV4, Sanofi Pasteur):***
  - 6 through 35 months previously received 0.25mL/dose
  - January 2019: FDA licensed 0.5mL/dose for all ages
    - Randomized non-inferiority trial of immunogenicity and safety of 0.25mL vs. 0.5mL in children aged 6 through 35 months presented to ACIP October 2018
  - Per labeling, 0.25mL or 0.5mL acceptable for 6 through 35 months

# Influenza Vaccines for Young Children

- **Less data and clinical experience with newer indications in this age group, particularly with concomitant receipt of other vaccines**
- **Five IIVs licensed for 6 through 35 months; dose volumes differ\*:**
  - *Fluarix Quadrivalent* (IIV4, GSK) 0.5mL
  - *FluLaval Quadrivalent* (IIV4, ID Biomedical Corp/GSK) 0.5 mL
  - *Fluzone Quadrivalent* (IIV4, Sanofi Pasteur) 0.25 mL or 0.5 mL
  - *Afluria* (IIV3, Seqirus) 0.25 mL
  - *Afluria Quadrivalent* (IIV4, Seqirus) 0.25 mL

\*Dose volume for persons aged  $\geq 3$  years is 0.5mL for all IIVs

# Vaccine Safety Datalink Study of IIV and SAB

- **Discussion of differences between the current and previous studies**
  - Matching
  - Study size/statistical power
  - Available vaccines (quadrivalent vs. trivalent)
- **Results felt to be reassuring overall**

# Upcoming WG Activities

- **Development of 2019-20 ACIP Influenza statement ongoing**
  - Further discussion at June 2019 ACIP meeting
  - No substantial changes anticipated at this time
  - Anticipated publication August, 2019
- **Discussion of 2018-19 influenza vaccine effectiveness data**
  - No estimate of LAIV effectiveness anticipated this season from U.S. Flu VE Network
- **General influenza vaccine safety update anticipated for June 2019 meeting**

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.